IJPSR (2020), Volume 11, Issue 4 (Review Article)

INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH

Received on 10 July 2019; received in revised form, 09 December 2019; accepted, 04 March 2020; published 01 April 2020

SUPERBUGS: THE POWERFUL WARRIORS

Samanjit Kaur [1], Sneha Hariharan [2] and Selvakumar Dharmaraj [*2]

Department of Biotechnology [1], Mohamed Sathak College of Art and Science, Sholinganallur - 600119, Tamil Nadu, India.
Department of Biochemistry [2], FASH, Karpagam Academy of Higher Education, Pollachi Main Road, Eachanari Post, Coimbatore - 641021, Tamil Nadu, India.

Keywords:

Multidrug resistance, Antibiotics, Superbugs

Correspondence to Author:
Dr. Selvakumar Dharmaraj

Assistant Professor,
Department of Biochemistry,
Karpagam Academy of Higher Education, Pollachi Main Road,
Eachanari Post, Coimbatore - 641021,
Tamil Nadu, India.

E-mail: sdharmaraj77@gmail.com

ABSTRACT: Antibiotics can no longer be considered as effective methods to treat various diseases. The misuse of these medicines has increased the evolvement of a number of drug-resistant microorganisms which are termed as "Superbugs". These are most prevalent in developing countries where the abuse of antibiotics is at the peak. *Clostridium difficile*, *Streptococcus pneumoniae*, MRSA (*Staphylococcus aureus*), ESBL (*Escherichia coli*) and NDM1 -*E. coli* were some of the top listed superbugs. Different kinds of these superbugs attack many countries; even the United States of America, which is under danger from 14 types of superbugs and has lost less than 14,000 individuals every year form *C. difficile* alone. An NDM-1 strain bacterium, most dangerous superbug, produces a protein that can able to kill the movement of carbapenem antibiotics, which are used to treat a broad range of infections in Hospitals and health care centers. These superbugs can affect an individual by cold, fever, non-healing factors, and lead to organ failures. International and National Organizations should take serious initiatives to curb this problem and providing guidelines to prevent the spreading of these infections. This review details the importance of Superbugs and explains some of the preventative measures.

INTRODUCTION: From the time of its discovery to till recently, antibiotics have given us a capable approach to treat infections that once were life-debilitating. Yet, the developing number of anti-microbial resistant microscopic organisms is putting this brilliant time of medication at danger. Presently, we end up in a race to keep bacterial infections from at the end of the day, turning into one of mankind's significant executioners. Anti-microbial resistance is a global issue.

QUICK RESPONSE CODE

DOI: 10.13040/IJPSR.0975-8232.11(4).1506-26

This article can be accessed online on www.ijpsr.com

DOI link: http://dx.doi.org/10.13040/IJPSR.0975-8232.11(4).1506-26

New types of anti-microbial resistance can cross worldwide limits and spread between the mainland effortlessly. Numerous types of resistance spread with momentous velocity. World well-being pioneers have depicted these safe anti-microbial microorganisms as bad dream microscopic organisms that represent a cataclysmic danger to individuals in each nation in the world [1].

World Health Organization (WHO) said in a report that antibiotic resistance microorganisms can influence anybody, of any age and in any nation. It is presently a noteworthy risk to general wellbeing and "the consequences will be devastating". In its first worldwide report on antibiotic resistance, with information from 114 nations, the WHO said superbugs are ready to sidestep occasion the hardest-hitting anti-infective agents - a class of

medications called carbapenems - have now been found in all the parts of the world. For gonorrhea, a risky sexually-transmitted sickness that infects more than a million individuals consistently all over the world, antibiotic medications are coming up short and quick as superbug types of the microbes that cause it to outpace them. Many countries including Austria, Australia, Britain, Canada, France, Japan, Norway, South Africa, Slovenia, and Sweden, now report having patients with gonorrhea that is absolutely untreatable.

Just a modest bunch of new antibiotic agents have been produced and gotten to advertise the in the previous couple of decades, and it is a race against time to discover more as bacterial diseases progressively advance into "superbugs" impervious to even the most capable final resort prescriptions saved for extreme cases. The WHO said that in a few nations, due to resistance, carbapenems now don't work in more than half of the individuals with regular doctor's facility procured diseases created by a microscopic organisms called *K. pneumoniae*, for example, pneumonia, blood infections, and diseases in infants and escalated care patients. Resistance to the most broadly utilized antibiotics agents for urinary tract diseases brought on by *E. coli* which pharmaceuticals called fluoroquinolones that is extremely far-reaching. According to the WHO reports, in the 1980s, when these medications were initially presented, resistance was for all intents and purposes zero, but be that as it may, now there are nations in numerous parts of the world where these medications are ineffectual in more than half of the patients [2].

The utilization of antibiotics is the absolute most vital component prompting anti-microbial resistance around the globe. Anti-infective agents are among the most ordinarily recommended medications utilized as a part of the human prescription. Nonetheless, up to half of the considerable number of anti-infective agents recommended for individuals are not required or are not ideally effective as prescribed. Anti-microbials are additionally utilized as a part of sustenance creatures to prevent, control, and treat infections, and to advance the development of nourishment delivering creatures. The utilization of anti-infective agents for advancing development is redundant, and the practice ought to be eliminated.

A harmful microorganism, ordinarily a bacterium is called a bug. "Superbugs" is a term used to describe strains of microorganisms that are resistant to the greater part of antimicrobials generally utilized today. Safe microscopic organisms that cause pneumonia, urinary tract diseases and skin infections are only a few risks we now confront. Numerous anti-toxin resistance qualities reside on plasmid, encouraging their exchange. A bacterium carrying a variety of antibiotic resistance genes is called multidrug-resistant or casually a Superbug or a super bacterium. Genes can be transferred between microscopic organisms in an even manner by Conjugation, Transduction or Transformation; therefore quality for anti-toxin resistance which had evolved by means of common choice may be shared. Some of the few Superbugs are: *Streptococcus pneumoniae*, MRSA (*S. aureus*), ESBL *Escherichia coli*, NDM1 - *E. coli* [3].

How Bacteria can Turn into a Superbugs? Bacteria can turn into superbugs with an introduction of NDM-1. The NDM-1 gene produces an enzyme that can digest a powerful antibiotic called carbapenem. Multidrug resistance gene in the bacterium makes it resistant to almost all antibiotic in **Table 1**. What does antibiotics do? in an expression utilized by microbiologists, it applies 'specific pressure' on bacteria. This bends and quickens their advancement so that already vulnerable species get resistance to the drug. To the same degree, this is just the consequence of Darwinian chance transformation. At the point when any bacterial species is assaulted by antibiotics, just the fittest survive. In any case, in a population of millions of bacteria, there will be some chance of mutants, possibly one in a million, and that simply happens to be immune to the drug that kills all the others. These already insignificant mutants survive, duplicate and colonize in the space left by the pulverization of the various bacteria in the species that were earlier helpless against the drug. So, in future, the antibiotic doesn't work. The making of superbugs is not simply a question of chance transformation; nonetheless, the bacteria are extremely complex and adaptable living organisms. Their genetic structures that evolved in order to resist naturally emerging chemicals contained in the host, pretty much as all the living things and, indeed, we human beings have developed intends to oppose predators.

TABLE 1: MODES OF ANTIBIOTIC ACTION

S. no.	Antibiotics	Antibiotic effects	Structure
		Interference with cell wall synthesis	
1	1. β-lactam antibiotics a. Penicillins b. Cephalosporin's	Disturb the enzymes needed for the peptidoglycan layer synthesis	
	2. Glycopeptides (Vancomycin, Ticoplanin, Oritavancin)	Binds to the D-alanyl-D-alanine termini of the peptidoglycan chain of the bacterial cell wall and thereby prevents the cross-linking	  
	3. Telavancin (Bactericidal lipoglycopeptide)	Prevents peptidoglycan biosynthesis by targeting transglycosylation mechanism	

		Inhibition of protein synthesis	
2	1. Macrolides	Binds to the 50S ribosomal subunit and interfere with the elongation of nascent polypeptide chains	 Macrolides
	2. Aminoglycosides	Binds to the 30S ribosomal subunit and inhibit the initiation of protein synthesis	 Aminoglycosides
	3. Chloramphenicol	Binds to the 50S ribosomal subunit blocking peptidyltransferase reaction	 Chloramphenicol
	4. Tetracyclines	Inhibit protein synthesis by binding to 30S subunit of the ribosome, thereby weakening the ribosome-tRNA interaction	 Tetracyclines
		Interference with nucleic acid synthesis	
3	1. Rifampicin	Interferes with a DNA-directed RNA polymerase	 Rifampicin
	2. Quinolones	Disrupt DNA synthesis by interference with type II topoisomerases DNA gyraseand topoisomerase IV during replicatin and by causing double-strand breaks	 Quinolones

	Inhibition of a metabolic pathway		
4	1. Sulfonamides (sulfamethoxazole) and Trimethoprim	1. Block the key steps in folate synthesis, which is a cofactor in the biosynthesis of nucleotides, the building blocks of DNA and RNA.	 Sulfonamides  Trimethoprim
	Disorganizing of the cell membrane		
5	1. Polymyxins	Exert their inhibitory effects by increasing bacterial membrane permeability, causing leakage of bacterial content.	Polymyxins 
	2. Cyclic lipopeptidedaptomycin	Displays rapid bactericidal activity by binding to the cytoplasmic membrane in a calcium-dependent manner and oligomerizing in the membrane, leading to an efflux of potassium from the bacterial cell and cell death.	Cyclic lipopeptidedaptomycin 



FIG. 1: RISE OF SUPERBUGS

These structures - rings of hereditary material contained inside of the bacterial cell wall notwithstanding the chromosome - are called plasmids. The codes for bacterial resistance to antibiotics are contained in plasmids. Under particular pressure from the drug, these codes can be exchanged inside of microscopic organisms of the same species, as well as from one species to others. Moreover, Plasmids may contain codes for resistance to one as well as to various antibiotics. Under pressure from a course of one drug, bacteria might, therefore, exchange various antibiotic resistance inside and between species. This means, as a consequence of taking the antibiotic drug, you could wind up with a gut loaded with bugs against which any number of future courses of antibiotics will be pointless. Antibiotic-resistant bacteria might themselves be the microbiological reason for unpalatable or even dangerous irresistible illness. If one takes antibiotics, such disease may spread from that individual to other **Fig. 1**. We cannot avoid superbugs by avoiding antibiotics and it might be present everywhere[4].

Spread of Superbugs: The superbugs can spread only through contact with an infected person, surfaces or via an intermediary such as hospital workers. Superbugs evolve best in hospital settings, though not exclusively as they have moved out into the community. Hospital is a place where people with compromised immune systems are widely seen. Superbugs are opportunistic and thrive in places with weak immunity. The bacterium is, however, dangerous to anyone who is ill or who has had an operation - making hospital patients particularly vulnerable. The most common way the infection is spread in hospitals is by the medical staff touching a patient who has the bacteria on their skin, then - without ensuring their hands are absolutely clean - moving on to another patient and passing on the bug into a wound. The bacteria can also survive away from the body - in the dust, in unwashed bedding, and on medical equipment. For patients, the most vulnerable time is during surgery when there are open wounds for the bacteria to enter into the bloodstream. Ironically, the very advances in medical science that keep so many people alive can also be lethal. Drips, monitors, ventilators, and dialysis equipment all provide avenues for bacteria to get into the bloodstream; symptoms can be in the form of boils, bone-joint infections or septicemia causing a raging, often deadly fever [5].

Countries Affected by Superbugs: Countries that are influenced by superbugs include the United States of America, Japan, India, Belgium, France, Bangladesh, Scotland, Pakistan, England, Northern Ireland, and Australia, *etc*.

India: Deadly superbugs are spreading all over India, killing a huge number of infants. More than 58,000 newborns died as an aftereffect of anti-infective safe bacterial infections. Medicines for these bugs are no longer effective because of the fact that the bacteria are transforming around them. According to the New York Times report, the microbes originate from different places, water, creatures, sewage, soil and even from the mother. This can be found at home or in the clinic. Due to a weak immune system of the babies, they can easily fall ill after exposure. About 33% of infant demise happens in India. Hospital births have gone up in India; however, with two or more mothers in every bed, contact with contaminated water and toilets, it's simple for microscopic organisms to spread. Specialists in India, make a big deal about their pay from selling medicines. If antibiotic infections continue to spread, advancement in preventing infants from gaining different infections "could moderate, stop or even invert itself and that would be a disaster for India as well as the whole world," quoted by Dr. Vinod Paul, head of pediatrics at the All India Institute of Medical Sciences, India and the study's pioneer, told the New York Times.

These children are a part of a disturbing outbreak. Analysts say that the proof is currently overpowering that a noteworthy offer of the microorganisms are present in India, in its water, sewage, creatures, soil and even in mothers, and these are resistant to almost all antibiotics. Newborns are especially powerless in light of the fact that they are delicate, leaving little time for specialists to discover a medication that works. But the risk of getting the infection is for everyone. Uppalapu Shrinivas, one of India's most well-known artists, passed at age 45 in light of infection that specialists couldn't cure. Tuberculosis is only one such illustration of the difficulties specialists face. India has the world's biggest number of cases, and late studies utilizing the most recent hereditary

tests have demonstrated that there is an upward of 10% of untreated patients in spots as far separated as Mumbai and Sikkim having the resistant infections. These patients are getting superbugs at home, not in hospitals, making the pandemic extremely hard to control, Dr. Soumya Swaminathan, executive of the National Institute for Research in Tuberculosis, said in an interview [5].

Japan: An untreatable strain of the sexually transmitted malady gonorrhea, impervious to every single existing anti-toxin, has been distinguished in Japan. The news takes after notices from the United States Centers for Disease Control (CDC) that it is just a matter of time before strong strains of *Neisseria gonorrhea* also starts to rise in the USA. The Japanese superbug, called H041, was separated by Magnus Unemo at the Örebro University Hospital in Sweden and has been reported for the current week at the International Society for Sexually Transmitted Disease Research meeting in Quebec, Canada. Unemo, who discovered the bug in strains from Kyoto, says that it could go worldwide in 10 to 20 years. The CDC reports that some gonorrhea strains in the USA can now be treated only with one class of anti-microbials, the cephalosporins. However, the Japanese superbug might yet meet its enemy. David Livermore, chief of the United Kingdom Health Protection Agency said that two lesser-known antibiotics namely Ertapenem and Spectinomycin, are the well on the way to have an action against it. But at the same time, the rise of the safe strain is aggravating. The disclosure adds weight to guidance for individuals with new or casual sexual partners to wear condoms, Livermore says. This is much more terrible than the AIDS [6].

United States of America: In the USA, somewhere around 5-10% of all patients admitted to intense consideration clinics (that is, those doctor's facilities that manage non-perpetual conditions) obtain one or more diseases while they arrive. This implies that more or less two million U.S. patients are consistently getting infected. Of these, 90 000 passes on as an aftereffect of their infection. As per a report from the Centers for Disease Control and Prevention in the year 2013, the USA is under danger from 14 superbugs representing a "pressing" or "genuine" risk, and thereby bringing about "concern" [7].

Britain: In Britain the most serious issue is MRSA, or methicillin-safe *Staphylococcus aureus*. In 1994, only 2% of staph infections in doctor's facility patients were MRSA; that figure has now ascended to 40 for every cent. Every year 300,000 British patients get a possibly life-debilitating disease in healing centers; 5000 of these will bite the dust. In 2002, 800 patients passed on from MRSA alone[7].

Canada: Canada has a superior record with some healing facility infections compared to the USA and Britain, however, the pattern is alarming. In 1995, for instance, the rate of staph diseases that were MRSA was 1%; this figure had exceeded 8% by 2000. Every year, around 200,000 Canadians experience the ill effects of the doctor's facility procured infection; and between 8500 and 12000 people die. Canada's most famous issue with healing facility gained diseases includes *C.difficile*, which has been particularly common in Quebec clinics. In the year between April 1, 2003, and March 31, 2004, there were 7004 instances of *C. difficile* in Quebec healing centers. Consequently, because of the infection, 1270 patients kicked the bucket. Not just has the infection rate risen significantly as of late, so has the passing rate by very nearly 60%. In 2000-01, 12% of the infected patients passed on. By 2003-04, 18% of the individuals who obtained the infection died. It is vital to note that a few nations have significantly higher rates of healing center gained anti-infective safe bacterial diseases than do these three nations. Hong Kong and South Africa, for instance, have rates as high as 80% of tainted patients. Be that as it may, one nation, The Netherlands, has possessed the capacity to hold the line strikingly well. On account of staph diseases, only one percent of Dutch cases are medication resistant[7].

Some Superbugs with High Threat Level:

***Clostridium difficile*:** It causes life-undermining loose bowels**.** This mostly causes infection in individuals who have had both late medicinal consideration and anti-microbials. Regularly, *C. difficile* diseases happen in hospitalized or as of late hospitalized patients. The microbes spread quickly on the grounds that it is normally impervious to numerous medications used to treat different diseases. In the year 2000, a more grounded strain of the microscopic organism developed.

This strain is resistant to fluoroquinolone anti-infective agents, which are normally used to treat different infections. This strain has spread all through North America and Europe, tainting and executing more individuals wherever it spreads.

Nearly 250,000 infections are obliging hospitalization or influencing officially hospitalized patients resulting in 14,000 deaths every year. At any rate, $1 billion in overabundance is being spent for therapeutic expenses every year. During somewhere around 2000 and 2007, demises identified with *C. difficile* increased to 400% to some extent as a result of a more grounded microscopic organism's strain that developed. Half of the diseases happen in individuals more youthful than 65, yet more than 90% of death happens in individuals of age 65 and above. Mostly the *C. difficile* infections first show side effects in hospitalized or as of late hospitalized patients, and then show indications in nursing home patients or in individuals as of late looked after in specialists' workplaces and clinics [8].

Carbapenem-Resistant Enterobacteriaceae: Untreatable and difficult to treat infections from Carbapenem-Resistant Enterobacteriaceae (CRE) microorganisms are on the ascent among patients in therapeutic centers. CRE have ended up impervious to all or almost all class of the anti-microbials we have today. Half of healing center patients who get circulatory system diseases from CRE micro-organisms don't survive. *Some Enterobacteriaceae* are impervious to almost all anti-toxins, including carbapenems, which are regularly viewed as the anti-toxins of the final option. More than 9,000 medicinal service-related diseases are brought on by CRE every year. CDC research centers have affirmed no less than one sort of CRE in medicinal service offices in 44 states. During the first half of 2012, about 4% of U.S. short-stay healing facilities had no less than one patient with a genuine CRE disease. Around 18% of long haul intense consideration healing facilities had one. An expected 140,000 medicinal service-related *Enterobacteriaceae* infections happen in the United States every year; of these around 9,300 are brought on by CRE. The majority of all circulatory system infections brought about by CRE result in death. Luckily, circulatory system diseases represent a minority of all social insurance-related infections created by *Enterobacteriaceae*. Every year, pretty nearly six hundred deaths result from diseases brought about by the two most regular types of CRE, carbapenem-resistant *Klebsiella* spp. and, carbapenem-resistant *E. coli* [9].

Drug-Resistant *Neisseria gonorrhoeae*: *Neisseria gonorrhoeae* causes gonorrhea, a sexually transmitted disease that can bring about release and aggravation at the urethra, cervix, pharynx, or rectum. *N. gonorrhoeae* is indicating resistance to anti-infective agents which typically used to treat it. These medications include Cefixime (an oral cephalosporin), Ceftriaxone (an injectable cephalosporin), azithromycin, and tetracycline. Gonorrhea is the second most commonly reported as the most prevalent disease in the United States and it is effortlessly transmitted. It causes serious regenerative inconveniences and excessively influences sexual, racial, and ethnic minorities.

Gonorrhea control depends on brief recognizable proof and treatment of the infected persons and their sex accomplices. Since only a few medications are less successful in treating gonorrhea, CDC recently redesigned its treatment rules to moderate the development of medication resistance. CDC now prescribes just ceftriaxone in addition to either azithromycin or doxycycline as first-line treatment for gonorrhea. The rise of cephalosporin resistance, particularly ceftriaxone resistance, would incredibly constrain the treatment alternatives and could disable gonorrhea control endeavors. In 2011, about 321,849 instances of gonorrhea were accounted to CDC, yet CDC estimates that more than 800,000 cases happen every year in the United States [10].

Multidrug-Resistant Acinetobacter: Multidrug-resistant Acinetobacter is a sort of gram-negative microorganisms that causes pneumonia or circulatory system infections among discrimi-natingly sick patients. A significant number of these microbes have turned out to be exceptionally impervious to anti-infective agents. Some Acinetobacter strains are impervious to about all or all antibiotic counting carbapenems that are regularly considered as anti-microbials of the final option. Around 63% of Acinetobacter is considered multidrug-resistant to no less than three distinct classes of anti-infective agents and hence has no

cure for the disease. Approximately 2% of social insurance-related infections answered to CDC's National Healthcare Safety Network are brought on by Acinetobacter, yet the extent is higher among discriminatingly sick patients on mechanical ventilators (around 7%). An expected 12,000 medicinal services related to Acinetobacter diseases happen in the United States every year. Almost 7,000 (or 63%) of these are multidrug-safe, and around five hundred deaths are ascribed to these diseases [11].

Drug-Resistant Campylobacter: Campylobacter generally causes the runs (regularly bleeding), fever, and stomach issues, and mostly causes genuine entanglements, for example, makeshift loss of motion. Doctors depend on medications like ciprofloxacin azithromycin for treating patients with extreme problems. Safe diseases generally are found to last more. Campylobacter shows resistance to ciprofloxacin, azithromycin. Campylobacter is evaluated to bring about around 1.3 million diseases, 13,000 hospitalizations, and 120 deaths every year in the United States. CDC is seeing imperviousness to ciprofloxacin in right around 25% of Campylobacter tried and imperviousness to azithromycin in around 2%. Expenses are required to be higher for safe infections in light of the fact that anti-microbial safe Campylobacter diseases are found to last more [12].

Fluconazole-Resistant Candida: Candidiasis is a contagious disease brought about by yeasts of the class Candida. There are more than 20 types of Candida yeasts that can bring about this disease in people, the most widely recognized of which is *Candida albicans*. Candida yeasts ordinarily live on the skin and mucous films without bringing on the infection. In any case, excess of these microorganisms can make side effects to develop. Side effects of Candida are changing contingent upon the body's region that is tainted. Candida is the fourth most normal reason for medicinal services related to circulatory system infections in the United States. In a few healing facilities it is the most widely recognized reason for such infections. These infections have a tendency to happen in the most debilitated of patients. Some Candida strains are progressively impervious to both first-line and second-line antifungal treatment operators.

Recent information exhibit a checked movement among diseases towards Candida species with expanded imperviousness to antifungal medications including azoles and echinocandins. CDC conducts multicenter reconnaissance for antifungal resistance in the United States, candidal infections, their monetary effect, and conceivable ranges where anticipation and control techniques can be engaged. An expected 46,000 social insurance-related Candida infections happen among hospitalized patients in the United States every year. About 30% of patients with circulatory system infections (Candidemia) with medication safe Candida bite the dust amid their hospitalization. CDC gauges that every instance of Candida disease results in 3–13 days of extra hospitalization, and an aggregate of $6,000–$29,000 in direct social insurance costs. Taking into account of these evaluations, safe Candida diseases may include a great many dollars in overabundance expenses to U.S. medicinal services every year [13].

Extended Spectrum β-Lactamase (ESBL) Producing Enterobacteriaceae: Extended-spectrum β-lactamase is a compound that permits microbes to end up impervious to a wide mixture of penicillins and cephalosporins. The bacteria which contain this chemical are known as ESBLs or ESBL-delivering bacteria. ESBL-delivering Enterobacteriaceae are impervious to solid anti-infective agents including expanded range cephalosporins. Some Enterobacteriaceae are impervious to almost all: penicillins, cephalosporins. In these cases, the remaining treatment alternative is an anti-toxin from the carbapenem gang. These are medications of final resort, and utilization of them is additionally adding to resistance. Almost 26,000 (or 19%) social insurance-related Enterobacteriaceae infections are created by ESBL-delivering Enterobacteriaceae. Patients with circulatory system diseases caused by ESBL-delivering Enterobacteriaceae are about 57% more prone to die than those with infections created by a non-ESBL-delivering strain. An expected 140,000 human services related to Entero-bacteriaceae diseases happen in the United States every year. CDC gauges that circulatory system infections brought about by ESBL-containing Entero-bacteriaceae results in upward of $40,000 in abundance of healing center charges per event.

Approximately 26,000 diseases and 1,700 passings were inferable from ESBLs [14].

Vancomycin-Resistant Enterococcus: Enterococci causes a scope of illness, for the most part, happen among patients accepting medicinal services, yet incorporates circulatory system diseases, surgical site infections, and urinary tract infections too. Enterococcus frequently causes diseases among exceptionally wiped outpatients in clinics and other human services settings. Some Enterococcus strains are impervious to vancomycin, an anti-microbial of final resort, leaving few or no treatment alternatives. Around 20,000 (or 30%) of Enterococcus human services related infections are vancomycin safe. An expected 66,000 social insurance related to Enterococcus diseases happen in the United States every year. The extent of diseases that happen with a vancomycin safe strain varies by the type of Enterococcus; generally, 20,000 vancomycin-safe infections happen among the hospitalized patients every year, with more or less 1,300 deaths ascribed to these diseases [15].

Multidrug-Resistant *Pseudomonas aeruginosa*: *Pseudomonas aeruginosa* is the common cause of healthcare-associated infections including pneumonia, bloodstream infections, urinary tract infections, and surgical site infections. Some strains of *P. aeruginosa* have been found to be resistant to nearly all or all antibiotics including amino-glycosides, cephalosporins, fluoroquinolones, and carbapenems. Approximately 8% of all healthcare-associated infections reported to CDC's National Healthcare Safety Network are caused by *P. aeruginosa*. About 13% of severe healthcare-associated infections caused by *P. aeruginosa* are multidrug-resistant, meaning several classes of antibiotics no longer cure these infections.

An estimated 51,000 healthcare-associated *P. aeruginosa* infections occur in the United States each year. More than 6,000 (or 13%) of these are multidrug-resistant, with roughly 400 deaths per year were attributed to these infections[16].

Methicillin-Resistant *Staphylococcus aureus*: Methicillin-resistant *Staphylococcus aureus* (MRSA) causes a range of illnesses, from skin and wound infections to pneumonia and bloodstream infections that can cause sepsis and death. Staph bacteria, including MRSA is one of the most common causes of healthcare-associated infections. Resistance to Methicillin, Cephalosporins, and related antibiotics like Nafcillin, Oxacillin are of high concern. CDC estimated that 80,461 invasive MRSA infections and 11,285 related deaths occurred in 2011. An unknown but much higher number of less severe infections occurred in both the community and in the healthcare settings [17].

Drug-Resistant *Streptococcus pneumoniae*: *Streptococcus pneumoniae* is the leading cause of bacterial pneumonia and meningitis in the United States. It is also the major cause of bloodstream infections and ear and sinus infections. *S. pneumoniae* has developed resistance to drugs in the penicillin and erythromycin groups. Examples of these drugs include amoxicillin and azithromycin (Zithromax, Z-Pak). *S. pneumoniae* has also developed resistance to less commonly used drugs. Pneumococcal disease, whether or not resistant to antibiotics, is a major public health problem. Pneumococcal disease causes 4 million disease episodes and 22,000 deaths annually. Pneumococcal ear infections (otitis media) are the most common type of pneumococcal disease among children, causing 1.5 million infections that often result in antibiotic use. Pneumococcal pneumonia is another important form of pneumococcal disease. Each year, nearly 160,000 children younger than 5 years old see doctors or are admitted to the hospital with pneumococcal pneumonia. Among adults, over 600,000 cases seek care for or are hospitalized with pneumococcal pneumonia. Pneumococcal pneumonia accounts for 72% of all direct medical costs for the treatment of pneumococcal disease. In 30% of severe *S. pneumoniae* cases, the bacteria are fully resistant to one or more clinically relevant antibiotics. Resistant infections can complicate the treatment and can result in almost 1,200,000 illnesses and 7,000 deaths per year.

Cases of resistant pneumococcal pneumonia result in about 32,000 additional doctor visits and about 19,000 additional hospitalizations each year. The excess costs associated with these cases are approximately $96 million. Invasive pneumococcal disease means that the bacteria invade parts of the body that are normally sterile, and when this happens, the disease is usually severe, causing hospitalization or even death.

The majority of such cases and deaths occur among adults age 50 years or older, with the highest rates among those who are 65 years or older. Almost everyone who gets this invasive pneumococcal disease needs treatment in hospital [18].

Drug-Resistant non-typhoidal Salmonella: Non-typhoidal Salmonella (serotypes other than Typhi, Paratyphi A, Paratyphi B, and Paratyphi C) for the most part cause looseness of the bowels (in some cases grisly), fever, and stomach spasms. A few diseases spread to the blood and can have life-debilitating difficulties. Physicians depend on medications, for example, ceftriaxone and ciprofloxacin, for treating patients with muddled *Salmonella* infections. Safe diseases are more serious and have higher hospitalization rates. Non-typhoidal Salmonella is demonstrating imperviousness to Ceftriaxone, Ciprofloxacin, and numerous class of other medications. Non-typhoidal *Salmonella* causes pretty nearly 1.2 million sicknesses, 23,000 hospitalizations, and 450 deaths every year in the United States. Direct medicinal expenses are evaluated to be $365 million every year. CDC is seeing imperviousness to ceftriaxone in around 3% of non-typhoidal *Salmonella* tried, and some level of imperviousness to ciprofloxacin in around 3%. Around 5% of non-typhoidal *Salmonella* tested by CDC are impervious to five or more sorts of medications. Expenses are relied upon to be higher for safety than for the powerless infections on the grounds that safe diseases are more extreme, and those patients are more inclined to be hospitalized, with the treatment being less viable [19].

Drug-Resistant *Salmonella Serotype typhi*: *Salmonella serotype typhi* causes typhoid fever, a conceivably life-undermining sickness. Individuals with typhoid fever, for the most part, have a high fever, stomach agony, and cerebral pain. Typhoid fever can prompt inside the aperture, stun, and demise. Doctors depend on medications, for example, Ceftriaxone, Azithromycin, and Ciprofloxacin for treating patients with typhoid fever. *Salmonella serotype typhi* is demonstrating imperviousness to Ceftriaxone, Azithromycin, Ciprofloxacin (resistance is common to the point that it can't be routinely utilized). *Salmonella typhi* causes pretty nearly 21.7 million sicknesses around the world.

In the United States, it causes pretty nearly 5,700 sicknesses and 620 hospitalizations every year. Most sicknesses happen in individuals who go to a few sections of the creating scene where the infection is normal. Travel-related infections are more inclined to be anti-infective safe. CDC is seeing some level of imperviousness to ciprofloxacin in 66% of *Salmonella typhi* tried. CDC has not yet seen imperviousness to ceftriaxone or azithromycin in the United States, yet this has been seen in other different parts of the world. Safe infections are prone to cost more than powerless diseases in light of the fact that the ailment may last more. Mortality due to this disease in the United States has become uncommon now, however before the use of anti-toxins, 10% to 20% of the patients died [20].

Drug-Resistant Shigella: *Shigella* sp., as a rule, causes looseness of the bowels (now and then bleeding), fever, and stomach torment. In some cases, it causes genuine complications, for example, responsive joint pain. High-hazard gatherings are incorporated in youthful youngsters, individuals with insufficient handwashing and cleanliness propensities, and men who engage in sexual relations with men. Resistance to customary first-line medications, for example, ampicillin trimethoprim-sulfamethoxazole has turned out to be high to the point that doctors now depend on optional medications like ciprofloxacin and azithromycin to treat the infections. Safe infections can last more than the diseases with vulnerable microorganisms (microscopic organisms that can be dealt with viably with anti-infective agents). *Shigella* is demonstrating imperviousness to ciprofloxacin, azithromycin. *Shigella* sp. causes roughly 500,000 diarrheal diseases, 5,500 hospitalizations, and 40 deaths every year in the United States. CDC is seeing imperviousness to ciprofloxacin in 1.6% of the *Shigella* cases tried and its imperviousness to azithromycin in 3% of the cases. Since introductory treatment can fizzle, expenses are required to be higher for safe infections [21].

Drug-Resistant Tuberculosis: Tuberculosis (TB) is among the most well-known irresistible sicknesses and a continuous reason for death around the world. TB is brought about by the microscopic organisms *Mycobacterium tuberculosis*

and it's airborne disease making it spread very normally in air. *M. tuberculosis* can influence any part of the body; however, ailment is discovered frequently in the lungs. As a rule, TB is treatable and reparable with the accessible first-line TB drugs; be that as it may, sometimes, M. tuberculosis can be impervious to one or a greater amount of the medications used to treat it. Drug-safe TB is all the more difficult to treat - it can be intricate and obliges additional time and more extravagant medications that regularly have more symptoms. Broadly Drug-Resistant TB (XDR TB) is impervious to most TB medications; along these lines, patients are left with treatment choices that are a great deal less compelling. The central point driving TB drug resistances are fragmented or wrong treatment, short medication supply, and the absence of new medications. In the United States, most medication safe TB is found among persons conceived it outside of the nation. Imperviousness to anti-infective agents is utilized for standard treatment. It also shows resistance to isoniazid (INH). Some TB is multidrug-safe (MDR), demonstrating imperviousness to in any event INH and rifampicin (RMP), which are the two fundamental first-line sedates. Some TB is XDR TB, characterized as MDR TB which shows in addition to imperviousness to any fluoroquinolone also shows resistance to any of the three second-line injectable medications (*i.e.*, amikacin, kanamycin, capreomycin) Of an aggregate of 10,528 instances of TB in the United States reported in 2011, anti-toxin resistance was recognized in 1,042, or 9.90%, of all TB, cases [22].

Vancomycin-Resistant *Staphylococcus aureus*: *Staphylococcus aureus* is a typical sort of microscopic organism that is found on the skin. Amid medicinal methods when patients oblige catheters or ventilators or experience surgical systems, *S. aureus* can enter the body and reason infections. At the point when *S. aureus* gets to be impervious to vancomycin, there are only a few treatment alternatives accessible in light of the fact that vancomycin-safe *S. aureus* microscopic organisms recognized to date were likewise impervious to methicillin and different classes of anti-infective agents. In rare cases, CDC has distinguished *S. aureus* that is impervious to vancomycin, the anti-toxin much frequently used to treat genuine *S. aureus* infections.

An aggregate of 13 instances of vancomycin-safe *S. aureus* (VRSA) has been recognized in the United States subsequent to 2002. VRSA disease continues to be an uncommon event. A couple of existing elements appear to incline patients to VRSA infection, includes Former MRSA and enterococcal diseases or colonization, Underlying conditions, (for example, unending skin ulcers and diabetes), and previous treatment with vancomycin [23].

Erythromycin-Resistant Group A *Streptococcus*: Group-A *Streptococcus* (GAS) causes many illnesses, including pharyngitis (strep throat), streptococcal toxic shock syndrome, necrotizing fasciitis ("flesh-eating" disease), scarlet fever, rheumatic fever, and skin infections such as impetigo. GAS has created resistance to clindamycin and to a class of medications called Tetracyclines. Macrolides incorporate erythromycin, azithromycin, and clarithromycin. GAS has likewise created imperviousness to a less generally utilized medication-tetracycline. Of these, imperviousness to erythromycin and the other macrolide anti-microbials is of the most prompt concern. Every year in the United States, erythromycin-safe, intrusive GAS causes 1,300 ailments and 160 deaths. GAS is the main source of upper respiratory tract diseases, for example, strep throat. There are 1-2.6 million instances of strep throat in the U.S. every year. These microscopic organisms are additionally the main source of necrotizing fasciitis, an intrusive infection that can be deadly in 25%-35% of the cases. Intrusive illness implies that microscopic organisms attack parts of the body that are regularly sterile. At the point when this happens, the malady is generally exceptionally serious, bringing on hospitalization or even passing. Those at most noteworthy dangers for obtrusive malady are the elderly, those with skin injuries, youthful youngsters, individuals in gathering living circumstances, for example, nursing homes, and those with basic medicinal conditions, for example, diabetes. Penicillin is the suggested first-line treatment for GAS infections.

Amoxicillin is a kind of penicillin that is frequently used to treat strep throat. Presently, GAS is not impervious to treatment with penicillin. On the off chance that imperviousness to penicillin rises, it would seriously bargain the treatment of obtrusive GAS diseases.

For individuals who are adversely resistant to penicillin, two of the optional anti-toxins, azithromycin, and clarithromycin, can be utilized to treat strep throat. Indeed, azithromycin is endorsed more regularly than penicillin. Of the GAS bacterial examples tried at CDC from 2010 and 2011, 10% were erythromycin-safe (and in this manner impervious to different macrolides, for example, azithromycin and clarithromycin), while 3.4% were clindamycin-safe. Expanding imperviousness to erythromycin will confuse the treatment of strep throat, especially for the individuals who can't endure penicillin. A more present concern is the increment in microbes that demonstrate the hereditary potential for getting to be impervious to clindamycin. Clindamycin has an interesting part in the treatment of extreme GAS infections. For extreme, life-debilitating diseases, such as necrotizing fasciitis and dangerous stun disorder, a mix of penicillin and clindamycin is suggested for treatment [24].

NDM-1 Superbug: Microscopic organisms (Bacteria) from clinical and non-clinical settings are turning out to be progressively resistant to antibiotics. 10 years prior, concern fixated on Gram-positive bacteria, particularly methicillin safe *Staphylococcus aureus* and vancomycin-safe *Enterococcus* spp. presently, however, clinical microbiologists progressively concur that multidrug-resistant Gram-negative microscopic organisms represent the most serious danger to general wellbeing. Not just is the increment in resistance of Gram-negative microbes quicker than in Gram-positive bacteria, additionally, there are less new and developmental antibiotics dynamic against Gram-negative bacteria [25]. Drug improvement projects appear insufficient to give remedial spread in 10-20 years [26, 27]. The increment in resistance of Gram-negative microorganisms is for the most part because of portable qualities on plasmids that can promptly spread through bacterial populaces. Institutionalized plasmid writing systems are upgrading our comprehension of the host scopes of these components and their overall distribution [28]. Moreover, uncommon human air travel and movement permit bacterial plasmids and clones to be transported quickly between nations and continents [29]. Much of this dispersal is undetected, with safe clones conveyed in the ordinary human flora and just getting to be apparent when they are the wellspring of endogenous infections. The CTX-M-15 augmented spectrum β-lactamase (ESBL) encoded by blaCTX-M-15 was first reported in India in the mid-1990s [30, 31]. The quality hopped from the chromosome of its regular hosts, Kluyvera spp, to plasmids that have therefore spread widely [32], building up CTX-M-15 as the comprehensively prevailing ESBL and the essential driver of gained imperviousness to third-generation cephalosporins in Entero-bacteriaceae [33].

Recent reviews have identified ESBLs in 70-90% of Enterobacteriaceae in India and; in spite of the fact that these accumulations may be a one-sided specimen, they do recommend a major issue, making the across the broad utilization of saved anti-toxins, for example, carbapenems necessarily. Rates of cephalosporin resistance are lower in different nations however, the developing pervasiveness of ESBL makers is sufficient to drive a more prominent dependence on carbapenems. Consequently, there is a choice weight for carbapenem resistance in Enterobacteriaceae, and its rise is an overall threat for general well being since there are a couple of anti-infective agents for the possible later use past carbapenems [34]. Already *Klebsiella pneumoniae* clones with KPC carbapenemase are a noteworthy issue in the USA, Greece, and Israel, and plasmids encoding the VIM metallo-carbapenemase have scattered among *K. pneumoniae* in Greece. As of late another kind of carbapenem resistance quality, assigned blaNDM-1was also reported [35]. A patient, repatriated to Sweden after admission to healing center in New Delhi, India, was colonized by *K. pneumoniae* and *E. coli* with blaNDM-1 on plasmids of shifting size, which promptly exchanged between bacterial strains in vitro. We looked for atomic, natural, and epidemiological information on New Delhi metallo-β-lactamase 1 (NDM-1) positive Entero-bacteriaceae in India and Pakistan and examined importation of the resistance quality into the UK by patients coming back from the Indian subcontinent [36].

NDM-1 Gene: NDM-1, which remains for New Delhi metallo-beta-lactamase-1 is a quality (DNA code) conveyed by some microbes. In the event that a microscopic organism strain conveys the NDM-1 quality is impervious to about all anti-

toxins, including carbapenem anti-infective agents-otherwise called the anti-microbials of last resort. It is encoded by a novel quality blaNDM-1.

Carbepenems are the most capable anti-toxins, utilized if all else fails for some bacterial diseases, for example, *E. coli* and *Klebsiella*.

The NDM-1 quality makes the bacterium deliver a protein that kills the movement of carbepenem antibiotics. The bacterium conveying the NDM-1 gene is the most effective superbug. New Delhi metallo-β-lactamase-1 (NDM-1) is a catalyst of β-lactamase family and as of late has been in the news after 'The Lancet Infectious Diseases' accounted for the overall vicinity of NDM-1 among a few bacterial animal varieties *viz*. *K. pneumonia, E. coli, E. cloacae, Proteus spp., Citrobacter freundii, K. oxytoca, M. morganii,* and *Providencia* spp, particularly in the Indian subcontinent area, where the misuse of anti-infective agents is more basic.

The NDM-1 is a novel sort of metallo-β-lactamase (MBL). The N and D of NDM stand for the city's name inception, which is of much contention, nowadays. The name was received after a typical practice; as VIM-1 (Verona integron encoded metallo-β-lactamase 1) was named after Verona, Italy [37]. The NDM-1 was initially reported in 2009 in a 59 year old Swedish tolerant, a diabetic male of an Indian starting point, who had received therapeutic treatment in New Delhi for gluteal boil and was again worked for decubital ulcer in December 2007. In January 2008, the patient went to a Swedish doctor's facility where a carbapenem-safe *K. pneumoniae* conveying the novel MBL was separated from his urine. Fecal specimens of this patient likewise demonstrated the vicinity of NDM-1 positive *E. coli* [38]. *K. pneumoniae* carbapenemases (KPCs) are β-lactamases delivered by Gram-negative bacteria. They productively hydrolyze penicillins, all cephalosporins, monobactams, carbapenems, and even β-lactamase inhibitors [39].

To date vicinity of NDM-1 have been accounted for in numerous nations including Sweden, United Kingdom, India, Pakistan, Bangladesh, Australia, Netherlands, USA, Canada, Japan, China and couple of days in a visitor from Taiwan, treated at doctor's facility in New Delhi in the wake of being extremely harmed in a terrorist assault in India. Many persons discovered constructive for conveying NDM-1 in Europe, U.S. furthermore, Japan had voyages to India or Pakistan or had received therapeutic treatment there for different reasons including; organ transplantation, dialysis, cardiovascular and respiratory framework infirmities, pregnancy, streetcar crashes, and corrective surgery demonstrates the high predominance of NDM-1 positive bacterial species in the Indian subcontinent. Based upon the amino corrosive arrangements beta-lactamases are grouped into 4 classes *i.e.* A, B, C, D. Enzymes from A, C, D contains serine-based dynamic site while class B, the EMBLs oblige a bivalent metal particle, usually Zn^{+2} for their action and it is the most heterogeneous class among the other classes of beta-lactamase. The fluoroquinolones, aminoglycosides, and β-lactams (extraordinarily carbapenems) are the major classes of anti-infective agents, dynamic against a gram-negative pathogen.

Carbapenems (imipenem, meropenem, ertapenem, faropenem, and doripenem) [40] is a class of β-lactam anti-toxins which acts by hindering the blend of bacterial cell divider [41]. The carbapenems are dynamic against the greater part of the β lactamases, and were created to overcome penicillin and cephalosporin safe microbes [42]. In spite of the fact that the blaNDM- 1 qualityin β-lactams safe microscopic organisms produces NDM-1, which is likewise alluded as carbapenemases is a sort of β-lactamase; a chemical that opens up the β-lactam ring and inactivates itis a matter of incredible concern as this class of anti-infective agents is backbone for the treatment of gram-negative pathogens [43]. They are frequently referred to as the last line of compelling anti-infective agents dynamic against multi-resistant Enterobacteriaceae most remarkably *Escherichia coli* and *Klebsiella pneumoniae*, which causes genuine nosocomial and group related bacterial diseases in people. Carbapenemases delivering microbes are frequently alluded to as superbugs, on the grounds that infections created by them are hard to treat. The carbapenemases are again separated into two noteworthy gatherings; one MBLs contains no less than one zinc iota at their dynamic site, can be inactivated by β-lactamase inhibitors and can be hindered by EDTA too while the second gathering serine-β-lactamases use serine at their dynamic locales, inactivated by

β-lactamase inhibitors, and can't be repressed by EDTA[44].

A joint study drove by Chennai based Karthikeyan Kumarasamy, at the University of Madras and UK based Timothy Walsh from a branch of invulnerability, disease and Biochemistry looked to analyze whether NDM-1 creating microscopic organisms were predominant in South Asia and Britain. In that study, the isolates of micro-organisms were recognized from Chennai and Haryana in India. The UK withdraws were distinguished from referrals to the Antibiotic Resistance Monitoring and Reference Laboratory by UK microbiology research offices somewhere around 2003 and 2009.

They moreover distinguished isolates from diverse areas around Bangladesh, India, and Pakistan. They recognized 44 secludes (isolates) with NDM-1 in Chennai, 26 in Haryana, 37 in the UK, and 73 in different locales in India and Pakistan. NDM-1 was basically found among *Escherichia coli* and *Klebsiella pneumonia*, which were exceedingly resistant to all anti-microbials but to tigecycline and colistin. *K. pneumoniae* confined from Haryana were clonal yet NDM-1 makers from the UK and Chennai were clonally differing. Most confines conveyed the NDM-1 quality on plasmids: those from UK and Chennai were promptly transferable though those from Haryana were not conjugative. A significant number of the UK NDM-1 positive patients had visits to India or Pakistan in the previous year or had joined with these nations [36].

Origin of Antibiotic Resistance: Resistance creates an opposition between ailment bringing about microscopic organisms and the microorganisms on which most antibiotics are based. In reality, resistance is not just a result of pharmaceuticals; numerous microbes are ordinarily ready to oppose various normal anti-toxins, delivering antibacterial substances to battle off contenders. When somebody takes an anti-infective, most microorganisms in the body are killed; however, the few surviving microscopic organisms regularly have a transferable hereditary component that not just secures them by creating proteins that battle off assault yet can likewise be effortlessly imparted to other microorganisms, in this way spreading resistance. What's more, is the all the more frequently the pathogenic microscopic organisms confront a specific medication, the all the more rapidly their safeguards advance. At the point when doctors overprescribe anti-toxins or recommend a wide range of drugs when a more focused on one would suffice, the process of resistance quickens. The most famous anti-infective safe life form is MRSA, the bacterium that causes savage skin diseases and doesn't react to penicillin or methicillin. MRSA flourishes in healing centers, a hotbed for anti-toxin resistance. Be that as it may, vancomycin-safe *Enterococci* (VRE) can likewise be risky, and different bugs, for example, *E. coli* and *Salmonella*, are additionally quickening the creating resistance.

In addition, about 33% of the pneumonia microbes in a few sections of the United States are currently less receptive to penicillin. The best response to medication resistance is new medications, yet on account of anti-infective agents, that is especially a difficult request. To discover today's 16 or something like that class of anti-infective agents, involving around 2,000 individual medications, researchers needed to filter through somewhere in the range of 10 million sorts of microorganisms. Be that as it may, with best mixes officially recognized, scientists will most likely need to test another 10 million equitable to locate one new class [45].

A random genetic mutation changes the reason that microbes get to be resistant. Some microorganisms twofold in numbers at a regular interval and a percentage of the new microscopic organisms are marginally unique in relation to the rest. In the event that the change is one that makes the bacterium impervious to the route in which it is focused by an anti-microbial, the transformed bacterium is given a colossal upper hand over other microorganisms, and it flourishes. The anti-toxin has made the bacterium more grounded and added to imperviousness to itself.

NDM-1 Symptoms: NDM-1 Symptoms are reported to be associated with the bacteria it attaches to. The currently known bacteria hosting the gene are *E. coli* and *K. pneumoniae*. The majority of the patients treated to date who are positive for NDM1 were those with G.I. tract infection, Urinary tract infection, blood poisoning

or pneumonia , skin boils in children to necrotizing fasciitis, or flesh-eating diseases. Many cause multiorgan failure leading to death [3]. Because NDM-1 can be carried by several types of gram-negative bacteria, the signs and symptoms of the diseases are of little or no help in distinguishing whether the patient has an organism expressing the enzyme until the antibiotic treatments fail. Failure of antibiotic treatments (oral or IV) to improve the patient's condition, especially if the patient is infected with a gram-negative bacterial type and is being treated with an antibiotic that contains a beta-lactam ring structure [46].

Controversy Regarding NDM-1 Naming: The gene was first named after New Delhi; the capital city of India, as it was 1st discovered in 2009in a Swedish national who fell ill with an antibiotic-resistant bacteria that he acquired in India. The infection was successfully treated in New Delhi hospital and after the patient's repatriation to Sweden, a carbapenem-resistant *Klebsiella pneumoniae* strain, bearing the novel gene was identified. The author concluded that the new resistance mechanism clearly arose in INDIA. But fortunately, India was supported by the Health Ministry and they gave positive comments like 1. It is unfortunate that the new bug, which is an Environment thing, has been attached to a particular country which is India in this case (Comment from health ministry). It is an attempt to hurt medical tourism in the country that is taking away huge customers from hospitals in the west (Comment from ICMR). "Such infections can flow in, from any part of the world. So, it is unfair to say it originated from India" [35].

Detection Methods of NDM-1: Carbapenem resistance and carbapenemase generation given by blaNDM-1 was recognized dependably with phenotypic testing routines, at present prescribed by the Clinical and Laboratory models Institute, including Disk Diffusion testing and the Modified Hodge Test [47].

Modified Hodge Test: Altered Hodge Test for Carbapenemase Detection in Enterobacteriaceae Background The Modified Hodge Test (MHT) recognizes carbapenemase production in isolates of Enterobacteriaceae. In the United States, the most widely recognized carbapenemase found in Enterobacteriaceae is the *Klebsiella pneumoniae* carbapenemase (KPC). Other carbapenemases, similar to the metallo β-lactamase (MBL) and the SME-1 in Serratiamarcescens, can likewise deliver a positive MHT, however, they are discovered occasionally in the United States. Reason Carbapenemase generation is identified by the MHT when the test confine produces the chemical and permits the development of a carbapenem vulnerable strain (*E. coli* ATCC 25922) towards a carbapenem plate. The outcome is a trademark cloverleaf-like indentation [48].

Disk Diffusion Method: In this technique, the creature to be tried is vaccinated over the whole surface of an M-H agar plate. Inoculation of the M-H agar plate is refined as portrayed by CSLI. It includes swabbing the whole surface three times in three unique bearings, to guarantee that life form develops on the whole surface of the plate, this is known as "law of development". Little channel paper circles, all containing diverse antimicrobial agents are then set on the agar surface. The plate is then upset and brooded for 16 to 18 h at 35 °C in non $-CO_2$ incubator. During incubation, drug diffuses into the agar plate and after hatching width of zone of hindrance was measured and contrasted or compared with zone sizes recorded on distributed diagrams to figure out whether the creature is susceptible, intermediate impervious (resistant) to the different medications were tested [49].

Hamilton, Ontario, July 6 (UPI): Researchers at McMaster University in Canada have added to another DNA-based strategy for testing for pathogens. They claim it is a great many times more effective than comparative tests in light of the fact that it works on a sub-atomic level, which will permit them to distinguish superbugs speedier than they beforehand could. The test does not include convoluted gear and will, in the end, be adjusted to a paper surface, wiping out the requirement for lab hardware. This could permit doctors to rapidly run the tests themselves."The system we have created permits us to distinguish focuses at levels that are exceptional," John Brennan, chief of McMaster University's Biointerfaces Institute, said in a press release. "The test has the best affectability ever reported for an identical arrangement of this kind - it is as much as 10,000 times touchier than other

location systems."The gadget is made of DNA that can be exchanged by particularly chosen atoms, for example, those of infection or microbes.

This causes a response showing the atoms' vicinity that is effectively distinguished. This atomic cooperation will make it less demanding to identify superbugs, for example, hepatitis C, *C. difficile* and MRSA are at lower levels than different tests. Researchers at McMaster beforehand created paper-based tests that can distinguish diseases and defilement. They plan to adjust the new DNA-based testing gadget to the paper group to make the testing system less demanding to utilize in about anyplace, for example, doctor's offices."This will be an establishment for us to make future indicative tests," said Yingfu Li, an educator at McMaster University. "This development will permit us to recognize anything we may be occupied with, bacterial defilement or maybe a protein atom that is a tumor marker. Our strategy can delicately distinguish every one of them, and it can do as such in a moderately brief duration of time [49].

Preventive Measures: The most basic and evident route is to keep the transmission of microscopic organisms on the first occasion through better cleanliness, clean water, a fixing of infection control hones inside of social insurance offices and vaccination. We should be proactive as opposed to reactive. (Professor Matt Cooper). In expansion, Professor Cooper is encouraging more research on new anti-toxins and the advancement of symptomatic tools. He said Australia is yet to make superbugs a need, with just 0.6 for each penny of the exploration spending plan spent on superbugs. In contrast, Europe and the US are spending colossal adds up to handle the problem.

The Federal Government discharged the first National Antimicrobial Resistance Strategy this year, illustrating suggestions to manage superbugs."It's an amazing record which has set a reasonable motivation for handling the issue," Professor Cooper said."But [superbugs] are a critical danger and we would prefer not to hold up an additional 10 years prior to the approach is enacted."One arrangement praised by Professor Cooper is compulsory reporting. Australia does not as of now have an approach or observation framework for reporting superbugs, he said. But the presentation of obligatory reporting abroad has had an immense effect on the levels of the disease, making medicinal services suppliers accountable [50]. Some preventive measures include:

- Reducing ecological infection or pollution: As clean environment will ensure that harmful microorganisms do not grow.
- Stop abusing or misusing Antibiotics: Antibiotics are only effective against bacterial infections, yet more than half of all antibiotics are unnecessarily given to people with infections caused by viruses such as colds and flu. Pressure from patients plays a role in this. When antibiotics are used in people who don't need them this increases resistance and leads to the development of superbugs. Check with your doctor if you really need antibiotics if you are offered them. And don't pressure your doctor for an antibiotic script if he or she thinks it will make little difference to your recovery.
- Patient's segregation or isolation: This will help in preventing the spread of harmful germs to a healthy person.
- Replace ordinary hostile to infection agents (Antibiotics) to peptide against disease operators.
- Without specialist’s prescription antibiotics should not be given in restorative medical shops.
- Disinfecting doctor's facility gear will likewise help in keeping the spread of sicknesses to unaffected people.
- Washing hands is the most perfect way to deal with keep any malady: Washing your hands much of the time – particularly prior and then afterward you eat, or after you come back from the washroom –this can restrain the exchange of microscopic organisms that cause superbugs furthermore also the spread of infections. The thought is you need to wash any microbes off from your hands before you carry them into contact with your eyes, nose or mouth. You additionally need to abstain from spreading microscopic organisms you may be

conveying. Washing your hands will help to lessen your shots of spreading microbes specifically to others, which you do through physical contact, or by touching soulless items, for example, entryway handles taps and handrails. Using normal cleanser and water or liquor rub will clean your hands and point of confinement for the spread of diseases.

- You ought to be mindful when you are traveling to different nations: as these microorganisms are more regular in food and water.

- Maintain your immunity or insusceptibility: When your immune system is compromised you leave yourself open to the risk of serious infections as you are not strong enough to combat any attacks. Maintain your eating habits in order to manage your nutritious food, take adequate rest, do follow regular workouts, and keeping up a vital separation from uneasiness all helps to keep you in incredible shape.

- Be cautious about therapeutic tourism: While undergoing treatment abroad, you ought to be aware of the risk of infections in hospitals in developing countries as these countries have higher rates of superbugs.

Some Precautions to Prevent Hospital Superbugs:

Try not to Shave: In case you're getting surgery on a body part you consistently shave, permit the stubble to develop in for a couple of days before the methodology. Regularly, the skin goes about as a defensive boundary against bugs, however, a razor leaves a trail of scratches and miniaturized scale cuts afterward, offering microorganisms welcoming section focuses on the body. Inquire as to whether they plan to evacuate hair around the entry point site; in the event that they say yes, let them know you'd favor they utilize scissors rather than a razor. Regardless of 30 years of experimental proof recommending that shaving treks the danger of disease, numerous specialists still do it to clear cut ranges, Streed says [30].

Kick the Habit: On the off chance that you smoke, attempt to stop or chop it down no less than a couple of days before any surgical system. Smoking diminishes the lungs' capacity to clean the blood of carbon dioxide and give it oxygen. At the point when denied of oxygen-rich blood, cells in the skin, for example, fibroblasts, in charge of recuperating injuries, turn out to be less effective. What's more, the more it takes these cells to shut off an injury, the additional time the bugs need to get inside [30].

Wash the Bugs Away: Clean the entry point site before surgery, in light of the fact that surgical blades and other surgical instruments regardless of how clean can drag microscopic organisms on the encompassing skin's surface into the cut. Numerous healing centers routinely send patients home with sterile chemicals and directions on the best way to bathe in readiness for operation. On the off chance that your doctor's facility is not one of them, purchase a germicide chemical containing the microscopic organisms executing fixing chlorhexidine gluconate (found in an item advertised as HIBICLENS) at your neighborhood drug store and use it to clean the surgical site and in addition, other body parts that tend to harbor microbes, for example, the underarms, crotch, and pubic territory the prior night and the morning of your operation. (The surgical group ought to additionally wash the entry point site just before the start of the operation.

Verify You're Kept Warm - The air temperature in working rooms ordinarily drifts somewhere around 65 and 69 degrees Fahrenheit (18 and 20 degrees Celsius). That is awesome for the specialists and medical caretakers packaged head to toe in scrubs, yet not so much for the individual on the table. Streed says that the body reacts to crisp air by tightening vessels supplying blood to the skin and the tissues just beneath it; occupying blood far from the body's surface and toward its center is the body's procedure for saving warmth. With less blood supplying oxygen to the cut site, the safe cells there get to be oxygen-denied and in this manner, less successful for the engaged attacking germs. Ask the surgical group how they plan to keep you warm on the off chance that they will wrench up the room temperature by a couple of degrees, spread you in covers, or warm you with IV liquids, for occurrence.

Get Some Information About Presurgery Anti-Infective Agents: For some operations, including those including the heart and bone, specialists routinely give patients preventive anti-infective agents to check infections from developing in any way. One measurement is commonly given through IV an hour before the specialists make the first cut, and once in a while two more dosages are given throughout the following 24 h, Streed says. On the off chance that you think any plausibility you have a disease before going into surgery, tell your specialist so that he or she can treat you first (Having a current infection in, say, the bladder or skins up the danger of adding to a second, surgery-related disease), Streed cautions.

Minimize Tubes: Each tube embedded into your body, from the IV supplying liquids to your arm vein to the catheter emptying pee of your bladder, goes about as "a superhighway for the bugs to enter [the body]," Streed says. Furthermore, the more drawn out the tubes are set up, the additional time the bugs need to hitch rides. Make sure to ask your specialist or medical attendant to uproot your IV or different tubes at the earliest opportunity after your surgery.

Know the Indications of Disease: Even though the doctor's facility takes every conceivable safety measure, you could at present get a disease. Some conceivable signs: a fever, wooziness, expanding agony, redness, warmth, swelling or discharge around the entry point and additionally inside your body. On the off chance that you encounter any of these side effects after surgery, alarm your specialist instantly.

Examine Your Doctor's Facility: Discover how well your doctor's facility has done controlling the infections. Twenty-six states have laws obliging clinics to freely reveal their disease rates; you can see whether your state is one of them by going to APIC's online enactment guide, says APIC representative Liz Garman. At that point, contacts your state's wellbeing office and ask where you can get healing center details; she exhorts. Other great wellsprings of information: Consumers Union's Stop Hospital Infections.org and the Committee to Reduce Infection Deaths' Hospital Infection Rates. Org - both Web locales give connections to infection reports.

Escape from the Healing Facility: "Consistently you're in the healing facility expands your danger of building up a disease," Streed says. "Work with your parental figures to meet recuperation objectives at the latest on the planned date. Get well and out of the doctor's facility ASAP.".

CONCLUSION: It is true that superbugs have become a challenging issue in the contemporary world. Even though we have encountered many kinds of these superbugs attack but still the number is growing gradually, and an immediate struggle is needed to come up with a proper solution. It has become very difficult for medical science to solve this enigma as it is getting stronger and stronger with each day and microbes are changing its surviving pattern at one time or another. The USA is claiming to solve some of the few superbug cases but they are not very dangerous unlike *Clostridium difficile*, Methicillin-Resistant *Staphylococcus aureus* (MRSA), New Delhi metallo-beta-lactamase-1 (NDM-1) *etc*. which are quite hard to win over them.

Countries like the USA, Japan, Canada, and United Kingdom can be affected by superbugs which are the centers of these antibiotic medicines then imagine what may happen to the underdeveloped and developing countries which are fully dependent upon the developed countries. Countries, where pastures are cultivated in large scale, are using more antibiotics for animals feed, which can create the right environment for superbug emergence and underdeveloped countries are creating this kind of environment by keeping hospitals untidy and unhygienic and availability of antibiotics without any prescription.

The definition of antibiotics may change in times if we won’t find a possible solution for these worldwide problems. Antibiotics are one of the miracles of modern medicines, but these superbugs have become a curse to medical science as they have turned resistant to these drugs. Antibiotic, which earlier used to solve the problems of TB, Cholera, and Diphtheria no longer show their potential as they have become prone to superbugs’ nature. Until we find a solution to eradicate this problem we just need to prevent it by that time with proper faith in medical science. Scientists are now looking forward to developing new antibiotics to

tackle this problem by starting with a new approach. They are using different modes to crack a way to overcome this problem as they are well aware of how serious this issue is, which cannot be defeated easily. We know well that the bacteria have survived the harshest conditions than us, so it'll not be easy to leave them behind. But scientists are understanding bacteria better than ever before, so we should not triumph overall; we just have to stay one step ahead.

ACKNOWLEDGEMENT: The author wishes to thank Karpagam Academy of Higher Education, Coimbatore, Tamil Nadu, India, for providing financial support for this study.

CONFLICTS OF INTEREST: The authors declare that there are no conflicts of interest.

REFERENCES:

1. Rajendran R: Superbug Infection. Journal of Drug Metabolism and Toxicology 2018; 9(2): 1-3.
2. Kate K: Superbugs' that can overpower antibiotics are spreading: WHO Health News 2014.
3. Alpert PT: Superbugs - Antibiotic resistance is becoming a major public health concern. Home Health Care Management and Practice 2016; 29(2): 130-33.
4. Renu B and Priti S: Antibiotic abuse: post-antibiotic apocalypse, superbugs and super foods. Current Science 2019; 116(7): 1055-56.
5. Chakraborty AK, Muneim GE, Pradhan S and Adhikari A: Superbug horror and its relations to antibiotics, probiotics and vitamins. Journal of Drugs and Ecotoxicology 2018; 1(1): 8-13.
6. Stuart AH, Thao LM and Jenny W: Gonorrhea – an evolving disease of the new millennium. Microbial Cell 2016; 3(9): 371-89.
7. Bilal A, Wei W, Muhammad IA, Mohsin K, Saima M, Muhammad HR, Muhammad AN, Ruman FA, Muhammad AA, Muhammad UQ, Muhammad KFS and Zulqarnain B: Antibiotic resistance - a rundown of a global crisis, Infection and Drug Resistance 2018; 11: 1645-58.
8. Angie MJ, Tomislav K, Mark ATB, Dena L and Matthew AC: *Clostridium difficile* drug pipeline: challenges in discovery and development of new agents. Journal of Medicinal Chemistry 2015; 58: 5164-85.
9. Francis SC and Eric SD: Carbapenem Resistance - A Review, Medicinal Sciences 2018; 6: 1-28.
10. Martin I, Sawatzky P, Allen V, Lefebvre B, Hoang LMN, Naidu P, Minion J, Van Caeseele P, Haldane D, Gad RR, Zahariadis G, Corriveau A, German G, Tomas K and Mulvey MR: Multidrug-resistant and extensively drug-resistant Neisseria gonorrhoeae in Canada, 2012–2016. Canadian Community Disease Rep 2019; 45(2/3): 45-53.
11. Yili C, Lu A, Penghao G, Han H, Zhongwen W, Xiaoling L and Kang L: Molecular characterization of multi drug resistant strains of *Acinetobacter baumannii* isolated from pediatric intensive care unit in a Chinese tertiary hospital, BMC Infectious Diseases 2018; 18(614): 1-7.
12. Schiaffino F, Colston JM, Paredes-Olortegui M, François R, Pisanic N, Burga R, Peñataro-Yori P and Kosek MN: Antibiotic resistance of *Campylobacter* species in a pediatric cohort study. Antimicrobial Agents and Chemotherapy 2019; 63(2): 1-10.
13. Elizabeth LB and Shawn RL: Fluconazole resistance in Candida species: a current perspective, Infection and Drug Resistance 2017; 10: 237-45.
14. Díaz-Agero Pérez C, López-Fresneña N, Rincon CAL, Marta HG, Patricia RG, Jesús MAA, Friederike M, Petra G, Marc JMB and Rafael C: Local prevalence of extended-spectrum beta-lactamase (ESBL) producing Entero-bacteriaceae intestinal carriers at admission and co-expression of ESBL and OXA-48 carbapenemase in *Klebsiella pneumoniae*: a prevalence survey in a Spanish University Hospital. BMJ Open 2019; 9: 1-6.
15. Tristan OD and Christopher WC: Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management. Infection and Drug Resistance 2015; 8: 217-30.
16. Sala A, Di Ianni F, Pelizzone I, Bertocchi M, Santospirito D, Rogato F, Flisi S, Spadini C, Iemmi T, Moggia E, Parmigiani E, Cavirani S, Taddei S and Cabassi CS: The prevalence of *Pseudomonas aeruginosa* and multidrug resistant *Pseudomonas aeruginosa* in healthy captive ophidian. PeerJ 2019; 7: 1-13.
17. Sahreena L and Kunyan Z: Methicillin-resistant *Staphylococcus aureus*: Molecular characterization, evolution, and Epidemiology Clinical Microbiology Reviews 2018; 31(4): 1-103.
18. Lindsay K, Lesley McGee, Sara T and Bernard B: Biological and epidemiological features of antibiotic-resistant *Streptococcus pneumonia* in pre- and post-conjugate vaccine eras: a United States perspective. Clinical Microbiology Review 2016; 29(3): 526-52.
19. Wang X, Biswas S, Paudyal N, Pan H, Li X, Fang W and Yue M: Antibiotic resistance in *Salmonella typhimurium* isolates recovered from the food chain through national antimicrobial resistance monitoring system between 1996 and 2016. Frontiers in Microbiology 2019; 10 (985): 1-12.
20. Britto CD, Wong VK, Dougan G and Pollard AJ: A systematic review of antimicrobial resistance in Salmonella entericaserovar Typhi, the etiological agent of typhoid. PLOS Neglected Tropical Diseases 2018; 12(10): 1-15.
21. Minakshi P, Mohan S and Pankaj C: Emergence of antibiotic-resistant Shigellaspecies: A matter of concern. Journal of Infection and Public Health 2018; 11: 451-54.
22. Kwonjune JS, Salmaan K and Michael LR: Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Cold Spring Harbour Perspectives in Medicine 2015; 5: 1-20.
23. Will AG, Natalia M and Frank RDL: Vancomycin resistance in *Staphylococcus aureus*. Yale Journal of Biology and Medicine 2017; 90: 269-81.
24. Hauwa MK, Azmiza SJ, Siti RAH, Nurul HU, Siti NAH and Rukman AH: Extremely Low prevalence of erythromycin-resistant *Streptococcus pyogenes* isolates and their molecular characteristics by M protein gene and multi-locus sequence typing methods. Jundishapur Journal of Microbiology 2018; 11(5): 1-7.
25. Baiden F, Owusu-Agyei S, Webster J and Chandramohan D: The need for new antibiotics. Lancet 2010; 375: 637-38.
26. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B and Bartlett J: Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clinical Infectious Disease 2009; 48: 1-12.

27. Page MG and Heim J: Prospects for the next anti-pseudomonas drug. Current Opinion in Pharmacology 2009; 9: 558-65.
28. Carattoli A: Resistance plasmid families in Entero-bacteriaceae. Antimicrobial Agents and Chemotherapy 2009; 53: 2227-38.
29. Walsh TR: Combinatorial genetic evolution of multi-resistance. Current Opinion in Microbiology 2006; 9: 476-82.
30. Hawkey PM: Prevalence and clonality of extended-spectrum betalactamases in Asia. Clinical Microbiology and Infection 2008; 14: 159-65.
31. Carattoli A, Miriagou V, Bertini A, Loli A, Colinon C, Villa L, Whichard JM and Rossolini GM: Replicon typing of plasmids encoding resistance to newer beta-lactams. Emerging Infectious Diseases 2006; 12: 1145-48.
32. Lartigue MF, Poirel L, Aubert D and Nordmann P: *In-vitro* analysis of ISEcp1B-mediated mobilization of naturally occurring β-lactamase gene blaCTX-M of Kluyvera ascorbata. Antimicrobial Agents and Chemotherapy 2006; 50: 1282-86.
33. Livermore DM, Canton R, Gniadkowski M, Nordmann P, Rossolini GM, Arlet G, Ayala J, Coque TM, Kern-Zdanowicz I, Luzzaro F, Poirel L and Woodford N: CTX-M: changing the face of ESBLs in Europe. Journal of Antimicrobial Chemotherapy 2007; 59: 165-74.
34. Livermore DM: Has the era of untreatable infections arrived? Journal of Antimicrobial Chemotherapy 2009; 64: 29-36.
35. Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K and Walsh TR: Characterization of a new metallo-β-lactamase gene, blaNDM-1, and a novel erythromycin esterase gene carried on a unique genetic structure in *K. pneumoniae* sequence type 14 from India. Antimicrobial Agents and Chemotherapy 2009; 53: 5046-54.
36. Kumarasamy KK, Toleman MR, Walsh TR, Bagaria J, Butt FA and Balakrishnan R: Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological Study. Lancet Infectious Diseases 2010; 10: 597-02.
37. Rolain JM, Parola P and Cornaglia G: New Delhi metallo-beta-lactamase (NDM-1): towards a new pandemia? Clinical Microbiology and Inf 2010; 16(12): 1699-01.
38. Nataraj G: New Delhi metallo beta-lactamase: What is in a name? Journal of Postgraduate Medicine 2010; 56: 251-52.
39. Papp-Wallace KM, Bethel CR, Distler AM, Kasuboski C, Taracila M and Bonomo RA: Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class-A β-lactamase. Antimicrobial Agents and Chemotherapy 2010; 54: 890-97.
40. Tripathi KD: Essentials of medical pharmacology. 6th Ed. New Delhi, India: Jaypee Brothers Medical Publishers (P) Ltd. 2008; 708-09.
41. Queenan AM and Bush K: Carbapenemases: the versatile beta-lactamases Clinical Microbiology Reviews 2007; 20: 440-58.
42. Branka B, Vanda P, Sanda S, Selma U and Karmen GT: Carbapenemases in gram-negative bacteria: laboratory detection and clinical significance. Biomedical Research International 2014; 1-3.
43. Patrice N and Laurent P: Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria. Clinical Infectious Diseases 2019; 69(7): 521-28.
44. Paul PC: The war on (antimicrobial) drugs: the fight against superbugs. Infectious Disease Special Edition 2018; 64-68.
45. Podolsky SH: The evolving response to antibiotic resistance (1945–2018). Palgrave Communications 2018; 4(124): 1-8.
46. Shyam SG, Ananya D, Nupur G, Inderjeet G, Jyoti B, Charoo H and Shashi K: New Delhi metallo-β-lactamase - type carbapenemases producing Escherichia coli isolates from hospitalized patients: A pilot study. Indian Journal of Medical Research 2017; 146: 105-10.
47. Amjad A, Mirza IA, Abbasi SA, Farwa U, Malik N and Zia F: Modified Hodge test: A simple and effective test for detection of carbapenemase production. Iranian Journal of Microbiology 2011; 3: 189-93.
48. Arpita P, Amit RS, Siddharth R and Subha G: Superbug, an emerging global threat in current scenario: a review. International Journal of Research Studies in Microbiology and Biotechnology 2016; 2(2): 15-19.
49. Silpi B, Priyanka S and Monali R: Multidrug-Resistant and Extensively Drug-Resistant Bacteria: A Study. Journal of Pathogens 2016; 1-5.
50. Miller JM, Binnicker MJ, Sheldon C, Carroll KC, Chapin KC, Gilligan PH, Gonzalez MD, Jerris RC, Kehl SC, Robin P, Pritt BS, Richter SS, Robinson-Dunn B, Schwartzman JD, Snyder JW, Telford Sam, Theel ES, Thomson RB, Weinstein MP and Yao JD: A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2018 update by the Infectious Diseases Society of America and the American Society for Microbiology. Clinical Infectious Diseases 2018; 67: 1-94.

How to cite this article:
Kaur S, Hariharan S and Dharmaraj S: Superbugs: the powerful warriors. Int J Pharm Sci & Res 2020; 11(4): 1506-26. doi: 10.13040/IJPSR.0975-8232.11(4).1506-26.